// App-Quantinova.ai

S2-03 : Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis Results from the adjuvant SUCCESS A trial

Researchers

Presenter

  • Janni W

Principal Investigators

  • Rack B

  • Fasching P

  • Mueller V

  • Schneewei A

  • Lichtenegger W

  • Beckmann M

  • Scholz C

  • Pantel K

  • Trapp E

  • Haeberle L

  • Friedl T

  • Tesch H

  • Lorenz R

  • Neugebauer J

  • Koch J

  • Jaeger B

  • Fehm T

Medical Centers

  • Medical Center Hamburg-Eppendorf, University Hospital Hamburg-Eppendorf, Hamburg, Germany

  • University Hospital Nuremberg-Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany

  • Charite University Hospital Campus Virchow, Berlin, Germany

  • University Hospital Heidelberg, Ruprecht-Karls-University, Heidelberg, Germany

  • Haemato-Oncology Practice, Bethanien Hospital, Frankfurt, Germany

  • University Hospital of the Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany.

  • University Hospital Ludwig-Maximilians University, Ludwig-Maximilians University, Munich, Germany

  • University Hospital Ulm, University of Ulm, Ulm, Germany

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Gynaecology Practice Lorenz/Hecker, Braunschweig, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Fluorouracil

  • Adrucil injection

  • Gemcitabine

  • Zolendronic acid

  • Epirubicin

  • Docetaxel

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved